NantHealth grew largely as a result of acquisitions in 2015 to 2016, just before it went public in mid-2016. Those acquisitions were not altogether strategic, as, over the ensuing 12 to 18 months, the company divested itself of these numerous healthcare software acquisitions to its partner, with whom it was actively competing with those very healthcare software applications. Moreover, the software applications were--and still are--commodities, which made for a difficult stack to sell. They were not aligned with the overall core oncology and precision medicine mission of the company, and proved to be expenses, rather than investments. Commensurate with this realization by fumbling executives, were 300 lay-offs in mid-2017, meant to save the company $70M, along with divestiture of these applications to its investment partner. The mission is noble, the company has potential, and the latest changes are probably smart, but the path taken has resulted in lots of human "roadkill" in its wake. Right now might be a better time to become involved with NantHealth, but, because of its narrowed focus and smaller workforce, it's probably not hiring. Most importantly, it still suffers from upper and mid-level management stupidity.
Cool and noble mission
Uphill battle to convince the market it needs NantHealth